Congenital Hyperinsulinism Treatment Market Size & Share 2023 to 2032
Market Size by Drug Type (Diazoxide, Octreotide, Nifedipine, Glucagon), Route of Administration (Oral, Parenteral), Distribution Channel (Retail Pharmacies, Hospital Pharmacies), Global Forecast.
Report ID: GMI6333
|
Published Date: July 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Congenital Hyperinsulinism Treatment Market Size
Congenital Hyperinsulinism Treatment Market size accounted for USD 146.4 million in 2022 and is estimated to grow at 5.5% to reach USD 251.1 million by 2032.
Congenital Hyperinsulinism Treatment Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Governments across various regions are increasingly recognizing the importance of addressing rare genetic disorders such as congenital hyperinsulinism (CHI) and are undertaking initiatives to support the development and accessibility of treatments. Through initiatives such as research grants, funding support, and regulatory incentives, governments are encouraging research and development in the field of rare diseases, thereby propelling the market growth. Furthermore, increasing focus on precision medicine is driving the development of targeted therapies for congenital hyperinsulinism, thereby accelerating the market progress.
Congenital hyperinsulinism (CHI) is a rare genetic disorder characterized by excessive insulin production from the pancreas, leading to recurrent and severe hypoglycemia (low blood sugar levels). The goal of CHI treatments is to maintain stable blood sugar levels and prevent hypoglycemic episodes, which can cause significant neurological complications.
COVID-19 Impact
The COVID-19 pandemic had a negative impact on the congenital hyperinsulinism (CHI) treatment market. Healthcare systems faced resource constraints and restructured their services to prioritize COVID-19 care, leading to delays in non-emergency medical services, including CHI treatment. This had resulted in delayed diagnosis and treatment for some CHI patients, thus impacted disease management and patient outcomes. Such aforementioned factor negatively impacted the market growth. Additionally, supply chain disruptions had resulted in shortages and delays in accessing critical medications and medical supplies required for CHI management, thereby hindered the market growth during the pandemic.
Congenital Hyperinsulinism Treatment Market Trends
The increasing prevalence of congenital hyperinsulinism (CHI) worldwide is anticipated to boost the market growth. For instance, according to the Orphanet Journal of Rare Diseases report, congenital hyperinsulinism has an estimated global prevalence of 1/50,000. Similarly, as per National Institute of Health (NIH) report, congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in new-born babies and children. In most countries, hyperinsulinism occurs in approximately 1/25,000 to 1/50,000 births. About 60% of babies with hyperinsulinism develop hypoglycemia during the first month of life. Thus, the increasing number of congenital hyperinsulinism cases globally has increased the demand for effective treatment options to manage this rare genetic disorder.
Congenital Hyperinsulinism Treatment Market Restraint
Limited approved treatment options for congenital hyperinsulinism may hamper the market growth. Due to the complexity and rarity of congenital hyperinsulinism (CHI), there is a lack of specific medications and therapies that have received regulatory approval for its management. Thus, the limited number of approved treatments poses challenges for healthcare providers and patients seeking treatment, thereby negatively impacting the market growth. Furthermore, the high cost associated with congenital hyperinsulinism treatment may hamper the market progress.
Congenital Hyperinsulinism Treatment Market Analysis
By drug type, the congenital hyperinsulinism treatment market is classified into diazoxide, octreotide, nifedipine, glucagon, and other drug types. The octreotide segment is projected to witness significant growth of 6.4% over the analysis timeframe. Octreotide is pivotal role in providing effective symptom management for individuals with congenital hyperinsulinism thereby, driving the segmental growth. Also, increasing number of drugs in the clinical trials will escalate the market growth. For instance, CRN04777 is an orally administered nonpeptide that is a potent and selective agonist of somatostatin 5 (SST5) receptors. It is currently under development for the treatment of congenital hyperinsulinism (HI), the most common cause of persistent hypoglycemia in new-borns and infants. Such development of novel drugs is anticipated to boost the market growth.
Based on route of administration, the congenital hyperinsulinism treatment market is segmented into oral and parenteral. The oral segment accounted for 60.7% of the market share in 2022. Oral medications offer a non-invasive and easy-to-administer option for managing congenital hyperinsulinism (CHI). Such factor is beneficial for pediatric patients and their caregivers. Also, the oral route eliminates the need for injections, thereby reduce discomfort and improve treatment compliance. Such associated benefits with oral route of administration is expected to foster the market growth. Moreover, the oral route of administration facilitates self-administration, thereby augmenting the overall market trends.
Based on distribution channel, the congenital hyperinsulinism treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies accounted for 45.3% of the market share in 2022. Hospital pharmacies play a crucial role in ensuring the timely availability of critical medications such as diazoxide and octreotide for treating congenital hyperinsulinism (CHI). Moreover, the close collaboration of hospital pharmacies with healthcare providers and specialists allows seamless coordination in delivering tailored treatment regimens to CHI patients, thus optimizing disease management and patient outcomes. Such aforementioned factors are expected to escalate the segmental expansion.
North America congenital hyperinsulinism treatment market accounted for 61.3% business share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. The region's advanced healthcare infrastructure and a strong focus on research and development is expected to supplement the market growth. Also, the favorable regulatory environment coupled with collaborations between pharmaceutical companies & research institutions will foster the development of new treatment options, thereby driving market growth. Further, the emphasis on patient-centric care and the availability of comprehensive medical services will contribute to the overall growth of the market in North America.
Congenital Hyperinsulinism Treatment Market Share
Major market players operating in the congenital hyperinsulinism treatment market include
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section includes both companies that have commercial drug available in market as well as those that are into clinical phase development.
Congenital Hyperinsulinism Treatment Industry News:
The congenital hyperinsulinism treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By drug type
Route of administration
Distribution channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →